Since arriving at Eli Lilly four years ago, CEO RANDALL L. TOBIAS has readied a slew of new products. And in '97, he reaped his reward. Lilly has five new drugs to offset its slowing workhorse, Prozac, including a hit drug for schizophrenia, Zyprexa. Better still, shareholders barely blinked last June when Tobias, 55, took a $2.4 billion write-off on his overpriced purchase of drug-benefits manager PCS Health Systems. The stock rose 92%, to hit an all-time high of 70.
Before it's here, it's on the Bloomberg Terminal. LEARN MORE